Recommended Conferences

  • Global Summit on Oncology & Cancer Theme: Redefining the Frontiers in Oncology Research
    March 12-14, 2018 Singapore
  • 22nd Global Annual Oncologists Meeting Theme: Welcoming the era of multiplying smiles not Cancer cells
    May 24-25, 2018 Osaka, Japan
  • World Haematology and Medical Oncology Conference Theme: An Eye towards “HAEMATOLOGY & MEDICAL ONCOLOGY”
    May 28-29, 2018 Osaka, Japan
  • Global Meeting on Oncology and Radiology Theme: Cancer Radiology - The Future Shape of Specialty
    June 1-2, 2018 Osaka,Japan

Dr. Ji-Liang Li

Dr. Ji-Liang Li Dr. Ji-Liang Li
Full professor and Chair in Tumour Immunology, Institute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD), UK.
 
Biography
Ji-Liang Li is a full professor and Chair in Tumour Immunology, at Institute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD), UK. He studied Medicine in 1982 and received his postgraduate training with Master of Medicine in 1986. He received his PhD from London University London School of Hygiene and Tropical Medicine in 1997 and experienced as Postdoctoral Research Associate in Department of Biochemistry at University of Oxford from 1996-1999, Research Fellow at Imperial Cancer Research Fund from 1999-2002, Tenured Staff Scientist/Deputy Lab Head in Cancer Research UK from 2002 to 2007, and then Tenured Scientist/Deputy Lab Head in Weatherall Institute of Molecular Medicine at University of Oxford from 2007-2015 prior to work at PUPSMD. He services as an editorial board member for a dozen of international journals. His current research interests are in tumour microenvironment, tumour metastasis, cancer biology and their translational medicine.
 
Research Interest
Tumour Microenvironment and Translational Cancer Medicine — Combination of cancer target therapy and immunotherapy — Tumour associated macrophages — Notch signalling in cancer biology — Tumour resistance to target therapy and immunotherapy — Hypoxia and angiogenesis pathways — Tumour MicroRNA and lncRNA
 

Relevant Conferences